|
Indications And Usage Iopidine ® (Apraclonidine Ophthalmic Solution) 0.5% Is Indicated For Short-Term Adjunctive Therapy, In Patients On Maximally Tolerated Medical Therapy, Who Require Additional Iop Reduction. Patients On Maximally Tolerated Medical Therapy, Who Are Treated With Iopidine ® (Apraclonidine Ophthalmic Solution) 0.5% To Delay Surgery, Should Have Frequent Follow-Up Examinations And Treatment Should Be Discontinued If The Iop Rises Significantly. The Addition Of Iopidine ® (Apraclonidine Ophthalmic Solution) 0.5% To Patients Already Using Two Aqueous Suppressing Drugs (I.e., Beta-Blocker Plus Carbonic Anhydrase Inhibitor) As Part Of Their Maximally Tolerated Medical Therapy May Not Provide Additional Benefit. This Is Because Iopidine ® (Apraclonidine Ophthalmic Solution) 0.5% Is An Aqueous Suppressing Drug And The Addition Of A Third Aqueous Suppressant May Not Significantly Reduce Iop. The Iop Lowering Efficacy Of Iopidine ® (Apraclonidine Ophthalmic Solution) 0.5% Diminishes Over Time In Some Patients. This Loss Of Effect, Or Tachyphylaxis, Appears To Be An Individual Occurrence With A Variable Time Of Onset And Should Be Closely Monitored. The Benefit For Most Patients Is Less Than One Month.
|